Denmark’s Odense University Hospital Orders Elekta’s New Versa HD Linear Accelerator for Radiotherapy Treatment of Patients with Cancer

Center to begin treating patients on two Versa HD systems in May
STOCKHOLM and ODENSE, March 14 – Odense University Hospital (OUH, Odense)
recently signed an order to acquire two Versa HD™ radiation therapy treatment
systems. On March 1, Elekta announced the global launch of Versa HD, an advanced
linear accelerator designed to improve patient care and treat a broader range of
cancers, and featuring ultra-conformal beam shaping and tumor targeting.

Versa HD promises the versatility to enable clinicians to deliver conventional
therapies to a wide range of tumors throughout the body, while also permitting
treatment of very complex cancers that require extreme targeting accuracy. Versa
HD also unveils new capabilities designed to maximize health care system
resources and deliver highly sophisticated therapies without compromising
treatment times.

“In the process of replacing two existing linear accelerators, we began
evaluating the systems of different vendors. Our focus was to acquire high-end
linear accelerators with fast and efficient dose delivery mainly for
stereotactic treatments, but also head-and-neck and lung cases,” says Knud Aage
Werenberg, head physicist at OUH. “We found that Elekta’s Versa HD – with its
highly conformal beam shaping technology and High Dose Rate mode – would fulfill
these requirements.”

The high doses employed in the treatment of typically very small targets in
stereotactic radiation therapy demand a system that combines high precision with
rapid beam delivery, he adds.

“Versa HD is equipped with Elekta’s Agility™ MLC, which has 160 high-speed
leaves for conforming closely to tumor margins and a flattening filter-free beam
generation for High Dose Rate mode,” Werenberg says. “Stereotactic treatments,
especially, will benefit from the system’s high dose rate capabilities, which
will reduce beam delivery time. Reduced beam-on time will result in less
intrafractional organ movement, meaning more dose to the target and less to
surrounding tissues – in addition to a much shorter treatment time. For example,
a stereotactic case that used to take 12 minutes might now take just five
minutes with Versa HD. This will also benefit the department by increasing the
number of patients we can treat per day.”

Advanced technology for common and complex cases
Versa HD incorporates technologies designed to provide an immediate impact to
patient health and quality of life. Integrated with Elekta’s revolutionary
Agility MLC, Versa HD provides highly conformal beam shaping – a critical
requirement for maximizing the dose to the target while also preserving
surrounding healthy tissues. Significantly, this high targeting accuracy is
available over a large field-of-view, permitting delivery of high-definition
(HD) beams to a broad spectrum of complex targets. Historically, high-definition
beam shaping often was mechanically limited to only small target therapies.
Versa HD with Agility overcomes this challenge, empowering clinicians to deliver
extremely precise beam contouring for both small and large targets.

Unprecedented combination of high dose rate delivery and rapid MLC leaf speed
Capable of delivering radiation doses three times faster than previous
generation Elekta linear accelerators, Versa HD harnesses the ultra-fast leaf
speeds of Agility MLC. With this groundbreaking combination, clinicians can now
– for the first time – fully exploit high dose rate delivery, potentially
enabling even greater capabilities for sophisticated therapies, including
stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT) and volumetric
modulated arc therapy (VMAT).

For more information, visit www.VersaHD.com.

Versa HD is not available for sale or distribution in all markets. Elements of
Versa HD are pending FDA 510(k) clearance.

# # #

For further information, please contact:
Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on March 14, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.